MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) is relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN plus DEX)

被引：0

作者：

Siegel, David Samuel DiCapua

Agajanian, Richy

Gaur, Rakesh

Karamiou, Kasra

Kaya, Hakan

Sturniolo, Michael

Ricafort, Rosanna J.

Larkins, Gall

Srinivasan, Shankar

Chopra, Rajosh

Thakurta, Anjan

Nagarwala, Yasir M.

Kruter, Flavio

机构：

[1] John Theurer Canc Ctr, Hackensack, NJ USA

[2] Oncol Inst Hope & Innovat, Downey, CA USA

[3] St Lukes Canc Inst, Kansas City, MO USA

[4] Bay Area Canc Res Grp, Pleasant Hill, CA USA

[5] Canc Care Northwest, Spokane, WA USA

[6] Celgene Corp, Summit, NJ USA

[7] Carroll Reg Canc Ctr, Westminister, MD USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.tps8627

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS8627

引用

页数：1